Protease inhibitors and cardiovascular outcomes in patients with HIV-1

• Published in: The Lancet (British edition) 2002-11, Vol.360 (9347), p.1747-1748
• Main Authors: Holmberg, Scott D, Moorman, Anne C, Williamson, John M, Tong, Tony C, Ward, Douglas J, Wood, Kathy C, Greenberg, Alan E, Janssen, Robert S
• Format: Article
• Language: English
• Subjects: Adult; Cardiovascular disease; Cohort Studies; Correlation coefficient; Drug therapy; Female; Heart attacks; HIV; HIV Infections - drug therapy; HIV-1; Human immunodeficiency virus; Humans; Hypertension; Male; Middle Aged; Myocardial infarction; Myocardial Infarction - chemically induced; Proportional Hazards Models; Protease Inhibitors - adverse effects; Protease Inhibitors - therapeutic use; Proteinase inhibitors; Proteins; Risk factors; Sexually transmitted diseases; STD
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(02)11672-2

Protease inhibitors for treatment of HIV-1 have been linked with increased risk of hyperlipidaemia and hyperglycaemia. In a cohort of 5672 outpatients with HIV-1 seen at nine US HIV clinics between January, 1993, and January, 2002, the frequency of myocardial infarctions increased after the introduction of protease inhibitors in 1996 (test for trend, p=0·0125). We noted that 19 of 3247 patients taking, but only two of 2425 who did not take, protease inhibitors had a myocardial infarction (odds ratio 7·1, 95% Cl 1·6–44·3; Cox proportional hazards model—adjusted for smoking, sex, age, diabetes, hyperlipidaemia, and hypertension—hazard ratio 6·5, 0·9–47·8). Our findings suggest that, although infrequent, use of protease inhibitors is associated with increased risk of myocardial infarction in patients with HIV-1.